Table 2.

Multivariable Risk Scores for Primary Prevention in Breast Cancer

Citation	Year	Follow‐Up	Treatment	N	Results of Predictive Risk Model—Primary Outcome	Factors Used to Calculate Risk of Cardiac Toxicity
Dranitsaris et al17	2008	3 mo	Anthracyclines	509	ROC AUC: 0.84 (95% CI, 0.79–0.89)—cardiac toxicity including CHF, hospitalization and need to stop therapy	Age, weight, baseline anthracycline exposure, previous mediastinal irradiation, cycle number WHO PS ≥1, vs 0, baseline LVEF <63%, adjuvant therapy
Ezaz et al18	2014	3 y	Trastuzumab	1664	Low (0–3): 16.2%; medium (4–5): 26%; high (≥6): 39.5%—heart failure or cardiomyopathy	Age, coronary artery disease, atrial fibrillation/flutter, diabetes mellitus, hypertension, renal failure, adjuvant therapy
Abdel‐Qadir et al16	2019	10 y (2003–2014/5)	Not specified	29 810	Wolber's C‐index, 5 y: −81.9% (80.9–82.9%); 10 y: 79.8% (78.8–80.8%)—major adverse cardiovascular events	Age, heart failure, atrial fibrillation, peripheral vascular disease, hypertension, ischemic heart disease, diabetes mellitus, chronic kidney disease, COPD, cerebrovascular disease

CHF indicates congestive heart failure; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; ROC AUC, receiver operating characteristic area under the curve; WHO PS, World Health Organization performance status.